> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nurix Stock Plunges 37%, Wiping Out $1 Billion, After Sanofi Ends Partnered Drug Program
- URL: https://www.bullished.co/nurix-stock-plunges-37-wiping-out-1-billion-after-sanofi-ends-partnered-drug-program-b69c52ae/
- Published: 2026-11-04T14:42:32.000Z
- Updated: 2026-11-04T14:42:32.000Z
- Description: Sanofi is terminating the oral STAT6 degrader program it shared with Nurix, though other licensed programs remain.
- Author: Matteo Parrino
- Tags: Markets, NRIX, Industry: Healthcare

[Nurix Therapeutics](https://www.bullished.co/tag/nrix/) shares fell 36.72% to $16.34 in Wednesday trading, as of 9:41 a.m. ET, erasing about $1 billion in market value, the session after partner Sanofi said it is ending its oral STAT6 degrader program. Nurix, which develops drugs designed to remove disease-causing proteins, disclosed the termination in an [8-K](https://www.sec.gov/Archives/edgar/data/0001549595/000154959526000055/nrix-20261103.htm?ref=bullished.co) filed Tuesday.

## Sanofi pulls the plug on STAT6

The filing says Sanofi has halted SAR448272 and shut the program down, ending its first-in-human study. Nurix loses all future payments tied to that program.

It can still earn milestones and royalties on the other programs licensed to Sanofi.

The stock was on pace for its biggest one-day drop in at least 275 trading sessions, since Oct. 1, 2025\. Its market value stood at about $1.8 billion after the drop.

## A run that ran into a partner exit

Nurix shares were up about 36% year to date at Tuesday's close, ahead of the S&P 500's gain of about 11%, and had risen 12% over the previous month.

In its [third-quarter results](https://www.sec.gov/Archives/edgar/data/0001549595/000154959526000048/nrix-20261013xexx991.htm?ref=bullished.co), the company said it earned $27 million from collaborations with Gilead, Pfizer and Sanofi. That included a $10 million milestone from Sanofi for dosing the first patient in this same STAT6 trial.

## What Nurix still has

The company has three clinical-stage candidates of its own: bexobrutideg and zelebrudomide, which degrade a protein called BTK, and NX-1607, which inhibits a protein called CBL-B. It also earns revenue from collaborations with Gilead, Sanofi and Pfizer.

In its latest results, Nurix said it dosed the first patient in a Phase 3 trial of bexobrutideg in chronic lymphocytic leukemia, a late-stage study run under its collaboration with Roche. It reported [$1.1 billion](https://www.sec.gov/Archives/edgar/data/0001549595/000154959526000048/nrix-20261013xexx991.htm?ref=bullished.co) in cash, cash equivalents and marketable securities, with a runway into the second half of 2029.

The Sanofi milestone Nurix booked last quarter was for starting the trial that is now being shut down.

### Sources

- [Nurix stock falls as Sanofi scraps partnered drug (NRIX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4664662-nurix-stock-falls-sanofi-scraps-partnered-drug?ref=bullished.co) — seekingalpha.com
- [NRIX Slumps 35% After-Hours — What’s Driving The Selloff?](https://finance.yahoo.com/markets/stocks/articles/nrix-slumps-35-hours-driving-225821967.html?ref=bullished.co) — Yahoo Finance
- [12 Health Care Stocks Moving In Wednesday's Pre-Market Session](https://www.benzinga.com/trading-ideas/movers/26/11/62858785/12-health-care-stocks-moving-wednesday-s-pre-market-session?ref=bullished.co) — benzinga.com
- [賽諾菲終止合作計劃，Nurix Therapeutics股價暴跌34%](https://hk.finance.yahoo.com/news/%E8%B3%BD%E8%AB%BE%E8%8F%B2%E7%B5%82%E6%AD%A2%E5%90%88%E4%BD%9C%E8%A8%88%E5%8A%83-nurix-therapeutics%E8%82%A1%E5%83%B9%E6%9A%B4%E8%B7%8C34-222420484.html?ref=bullished.co) — Yahoo Finance
- [Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session](https://www.benzinga.com/trading-ideas/movers/26/11/62861600/amdocs-posts-downbeat-q4-earnings-joins-skyworks-solutions-tesla-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session?ref=bullished.co) — benzinga.com
- [The company's filing (Nurix Therapeutics)](https://www.sec.gov/Archives/edgar/data/0001549595/000154959526000055/nrix-20261103.htm?ref=bullished.co) — SEC filing
- [Nurix Therapeutics — Form 10-Q for the quarter ended 2026-08-31 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm?ref=bullished.co) — SEC EDGAR
- [Nurix Therapeutics — earnings release (Form 8-K, Item 2.02), filed 2026-10-13](https://www.sec.gov/Archives/edgar/data/0001549595/000154959526000048/nrix-20261013xexx991.htm?ref=bullished.co) — SEC EDGAR

### More on Nurix Therapeutics

- [Sanofi Ends Trial Of STAT6 Degrader, Wiping Out Nurix's Milestone And Royalty Prospects On It](https://www.bullished.co/sanofi-ends-trial-of-stat6-degrader-wiping-out-nurixs-milestone-and-royalty-prospects-on-391bb5b5/)
- [Nurix's 10-Q Books $653.2 Million Of Roche's $700 Million Upfront As License Revenue, Flipping A Nine-Month Loss To Profit](https://www.bullished.co/nurixs-10-q-books-653-2-million-of-roches-700-million-upfront-as-license-revenue-flipping-dc7d6bca/)
- [Nurix Posts $549.8 Million Quarterly Profit After Roche Collaboration Revenue, Against An $86.4 Million Loss](https://www.bullished.co/nurix-posts-549-8-million-quarterly-profit-after-roche-collaboration-revenue-against-an-86-384e6f4b/)

[All Nurix Therapeutics (NRIX) coverage →](https://www.bullished.co/tag/nrix/)